AI
HAE icon

Atom Investors’s Haemonetics HAE Stock Holding History

Atom Investors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-22,521
Closed -$1.1M – 678
2025
Q3 		$1.1M Sell
22,521
-23,454
-51% -$1.45M 0.08% 241
2025
Q2 		$3.43M Sell
45,975
-6,820
-13% -$452K 0.3% 89
2025
Q1 		$3.36M Sell
52,795
-10,647
-17% -$724K 0.41% 70
2024
Q4 		$4.95M Buy
63,442
+43,897
+225% +$3.53M 0.62% 28
2024
Q3 		$1.57M Buy
+19,545
New +$1.58M 0.16% 187
2020
Q1 		– Sell
-53,851
Closed -$6.19M – 349
2019
Q4 		$6.19M Sell
53,851
-15
-0% -$1.81K 0.51% 63
2019
Q3 		$6.79M Buy
53,866
+10,779
+25% +$1.37M 0.46% 76
2019
Q2 		$5.18M Buy
+43,087
New +$4.24M 0.34% 94

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Atom Investors's HAE Position: Q4 2025 in Review

Atom Investors sold out of Haemonetics (HAE) in Q4 2025, closing a stake of 22,521 shares — an estimated $1.1M sold.

Atom Investors first reported a position in HAE in Q2 2019 and held it in 8 quarters. The position peaked at $6.79M in Q3 2019. 329 funds tracked by Wall St. Rank hold HAE as of Q4 2025.

  • Atom Investors reported no remaining Haemonetics position as of Q4 2025 after selling out during the quarter.
  • Atom Investors sold 22,521 Haemonetics shares in Q4 2025, an estimated $1.1M.
  • Atom Investors first reported a position in Haemonetics in Q2 2019 and held it in 8 quarters.
  • Atom Investors's Haemonetics position peaked at $6.79M in Q3 2019.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.